The total number of records retrieved from this search are 12. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_4401	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineSt. Joseph healthcare, London	Origin of cell lineHuman head and neck squamous cell carcinoma	Cell lineHN-5a	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical method	In-vitro virus concentration16.64+/- 1.41	In-vitro result20% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedIncrease in apoptosis upto 25%	Immunogenic effectNA	Clinical trialNA	PMID26429639
IDOV_4402	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineSt. Joseph healthcare, London	Origin of cell lineHuman head and neck squamous cell carcinoma	Cell lineHN-5a	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical method	In-vitro virus concentration57.46+/- 8.37	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedIncrease in apoptosis upto 25%	Immunogenic effectNA	Clinical trialNA	PMID26429639
IDOV_4403	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineSt. Joseph healthcare, London	Origin of cell lineHuman head and neck squamous cell carcinoma	Cell lineHN-5a	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical method	In-vitro virus concentration96.31+/- 10.76	In-vitro result70% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedIncrease in apoptosis upto 25%	Immunogenic effectNA	Clinical trialNA	PMID26429639
IDOV_4404	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineSt. Joseph healthcare, London	Origin of cell lineHuman head and neck squamous cell carcinoma	Cell lineHN-5a/carbo-15a	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical method	In-vitro virus concentration16.56+/- 2.78	In-vitro result20% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedIncrease in apoptosis upto 25%	Immunogenic effectNA	Clinical trialNA	PMID26429639
IDOV_4405	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineSt. Joseph healthcare, London	Origin of cell lineHuman head and neck squamous cell carcinoma	Cell lineHN-5a/carbo-15a	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical method	In-vitro virus concentration52.17+/- 9.68	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedIncrease in apoptosis upto 25%	Immunogenic effectNA	Clinical trialNA	PMID26429639
IDOV_4406	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineSt. Joseph healthcare, London	Origin of cell lineHuman head and neck squamous cell carcinoma	Cell lineHN-5a/carbo-15a	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical method	In-vitro virus concentration90.13+/- 14.42	In-vitro result70% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedIncrease in apoptosis upto 25%	Immunogenic effectNA	Clinical trialNA	PMID26429639
IDOV_4416	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with melphalan (2.5 microgram)	Immune gene insertion in viral genomeNo	Source of cell lineSt. Joseph healthcare, London	Origin of cell lineHuman head and neck squamous cell carcinoma	Cell lineHN-5a	Concentration of cell lineNA	In-vitro toxicityNA	AssayFlow cytometry	In-vitro virus concentration20 pfu	In-vitro result3% cancer cell death after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedIncrease in apoptosis upto 25%	Immunogenic effectNA	Clinical trialNA	PMID26429639
IDOV_4417	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with melphalan (5 microgram)	Immune gene insertion in viral genomeNo	Source of cell lineSt. Joseph healthcare, London	Origin of cell lineHuman head and neck squamous cell carcinoma	Cell lineHN-5a	Concentration of cell lineNA	In-vitro toxicityNA	AssayFlow cytometry	In-vitro virus concentration20 pfu	In-vitro result6% cancer cell death after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedIncrease in apoptosis upto 25%	Immunogenic effectNA	Clinical trialNA	PMID26429639
IDOV_4418	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with melphalan (7.5 microgram)	Immune gene insertion in viral genomeNo	Source of cell lineSt. Joseph healthcare, London	Origin of cell lineHuman head and neck squamous cell carcinoma	Cell lineHN-5a	Concentration of cell lineNA	In-vitro toxicityNA	AssayFlow cytometry	In-vitro virus concentration20 pfu	In-vitro result10% cancer cell death after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedIncrease in apoptosis upto 25%	Immunogenic effectNA	Clinical trialNA	PMID26429639
IDOV_4419	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with melphalan (2.5 microgram)	Immune gene insertion in viral genomeNo	Source of cell lineSt. Joseph healthcare, London	Origin of cell lineHuman head and neck squamous cell carcinoma	Cell lineHN-5a	Concentration of cell lineNA	In-vitro toxicityNA	AssayFlow cytometry	In-vitro virus concentration20 pfu	In-vitro result3% cancer cell death after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedIncrease in apoptosis upto 25%	Immunogenic effectNA	Clinical trialNA	PMID26429639
IDOV_4420	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with melphalan (5 microgram)	Immune gene insertion in viral genomeNo	Source of cell lineSt. Joseph healthcare, London	Origin of cell lineHuman head and neck squamous cell carcinoma	Cell lineHN-5a	Concentration of cell lineNA	In-vitro toxicityNA	AssayFlow cytometry	In-vitro virus concentration20 pfu	In-vitro result15% cancer cell death after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedIncrease in apoptosis upto 25%	Immunogenic effectNA	Clinical trialNA	PMID26429639
IDOV_4421	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with melphalan (7.5 microgram)	Immune gene insertion in viral genomeNo	Source of cell lineSt. Joseph healthcare, London	Origin of cell lineHuman head and neck squamous cell carcinoma	Cell lineHN-5a	Concentration of cell lineNA	In-vitro toxicityNA	AssayFlow cytometry	In-vitro virus concentration20 pfu	In-vitro result25% cancer cell death after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedIncrease in apoptosis upto 25%	Immunogenic effectNA	Clinical trialNA	PMID26429639